Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease

BACKGROUND: Intraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson’s disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [(18)F]DOPA uptake throu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Parkinsons Dis
Main Authors: Whone, Alan L., Boca, Mihaela, Luz, Matthias, Woolley, Max, Mooney, Lucy, Dharia, Sonali, Broadfoot, Jack, Cronin, David, Schroers, Christian, Barua, Neil U., Longpre, Lara, Barclay, C. Lynn, Boiko, Chris, Johnson, Greg A., Fibiger, H. Christian, Harrison, Rob, Lewis, Owen, Pritchard, Gemma, Howell, Mike, Irving, Charlie, Johnson, David, Kinch, Suk, Marshall, Christopher, Lawrence, Andrew D., Blinder, Stephan, Sossi, Vesna, Stoessl, A. Jon, Skinner, Paul, Mohr, Erich, Gill, Steven S.
Formato: Artigo
Idioma:Inglês
Publicado em: IOS Press 2019
Assuntos:
Research Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6597995/
https://ncbi.nlm.nih.gov/pubmed/30829619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-191576
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados